UPDATE: Bank of America Reiterates Buy Rating, Raises PT on DaVita HealthCare Partners After Strong Quarter

In a report published Friday, Bank of America reiterated its Buy rating on DaVita HealthCare Partners (NYSE: DVA ), and raised its price target from $134.00 to $138.00. Bank of America noted, “DVA reported a strong quarter with EBITDA $15m above our est as both segments did better than guidance